leadf
logo-loader
viewCardiex Ltd

Full interview: CardieX CEO provides significant corporate update including participation in COVID clinical trial

 

CardieX (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive Vancouver to discuss a number of updates with the company including the use of their XCEL SphygmoCor device by researchers in a clinical study by the Artery Society on COVID and arterial stiffness.

Cooper discusses that study and also gave Proactive some new information regarding Swiss company Roche selecting CardieX co-development partner Blumio for a medical-grade diagnostic sensor pilot program and Blumio's new development agreement with Infineon.

Quick facts: Cardiex Ltd

Price: 0.052 AUD

ASX:CDX
Market: ASX
Market Cap: $43.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiex Ltd named herein, including the promotion by the Company of Cardiex Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CardieX Limited signs disruptive deal with Chinese medical device company Andon

CardieX Limited (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive with news the company has entered a co-development and commercial partnership agreement with Andon. Andon is one of China’s largest manufacturers of home-use medical electronic devices. Cooper talks about the deal...

on 9/9/20

2 min read